{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:10:32Z","timestamp":1758705032623,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.humpath.2022.05.011","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T11:17:51Z","timestamp":1653391071000},"page":"129-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Digital imaging correlation of immunohistochemistry and fluorescence in situ hybridization in breast carcinoma cases with HER2 genetic heterogeneity"],"prefix":"10.1016","volume":"126","author":[{"given":"Diane M.","family":"Wilcock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepika","family":"Sirohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua F.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Evin","family":"Gulbahce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2022.05.011_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2022.05.011_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2022.05.011_bib3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2022.05.011_bib4","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.2001.19.6.1865","article-title":"2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Bast","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2022.05.011_bib5","doi-asserted-by":"crossref","first-page":"966","DOI":"10.5858\/2000-124-0966-PFIBC","article-title":"Prognostic factors in breast cancer. College of American Pathologists consensus statement 1999","volume":"124","author":"Fitzgibbons","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2022.05.011_bib6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1309\/AJCP51HCGPOPWSCY","article-title":"Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab","volume":"144","author":"Lee","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/01.LAB.0000032371.16521.40","article-title":"Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer","volume":"82","author":"Glockner","year":"2002","journal-title":"Lab Invest"},{"key":"10.1016\/j.humpath.2022.05.011_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1524-4741.1999.97088.x","article-title":"Marked intratumoral heterogeneity of the proto-oncogene Her-2\/neu determined by three different detection systems","volume":"5","author":"Pertschuk","year":"1999","journal-title":"Breast J"},{"key":"10.1016\/j.humpath.2022.05.011_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00129039-200403000-00003","article-title":"HER-2\/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components","volume":"12","author":"Andersson","year":"2004","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2022.05.011_bib10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/modpathol.2012.36","article-title":"Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance","volume":"25","author":"Seol","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/jclinpath-2012-201403","article-title":"Clinicopathological significance of HER2\/neu genetic heterogeneity in HER2\/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis","volume":"66","author":"Shafi","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1309\/AJCPIRL4GUVGK3YX","article-title":"HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer","volume":"142","author":"Lee","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCP0EN6AQMWETZZ","article-title":"Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition","volume":"136","author":"Bartlett","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/modpathol.2011.206","article-title":"\u2018Genetic heterogeneity\u2019 in HER2\/neu testing by fluorescence in situ hybridization: a study of 2,522 cases","volume":"25","author":"Chang","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib15","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1309\/AJCP09VUTZWZXBMJ","article-title":"Genotypic intratumoral heterogeneity in breast carcinoma with HER2\/neu amplification: evaluation according to ASCO\/CAP criteria","volume":"131","author":"Brunelli","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2022.05.011_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.5858\/133.4.611","article-title":"Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines","volume":"133","author":"Vance","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.humpath.2022.05.011_bib18","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2022.05.011_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1309\/J9VXABUGKC4Y07DL","article-title":"Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining","volume":"124","author":"Lewis","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib20","doi-asserted-by":"crossref","first-page":"2321916","DOI":"10.1155\/2017\/2321916","article-title":"Automated image analysis of HER2 fluorescence in situ hybridization to refine definitions of genetic heterogeneity in breast cancer tissue","volume":"2017","author":"Radziuviene","year":"2017","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.humpath.2022.05.011_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2013.103","article-title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","volume":"27","author":"Hanna","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ajcp\/aqz010","article-title":"Pathologic features and clinical implications of breast cancer with HER2 intratumoral genetic heterogeneity","volume":"152","author":"Muller","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib23","doi-asserted-by":"crossref","first-page":"23383","DOI":"10.1038\/srep23383","article-title":"Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment","volume":"6","author":"Buckley","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2022.05.011_bib24","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1097\/PAS.0000000000001100","article-title":"The dilemma of HER2 double-equivocal breast carcinomas: genomic profiling and implications for treatment","volume":"42","author":"Marchio","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib25","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10549-012-2046-0","article-title":"Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance","volume":"134","author":"Yang","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.humpath.2022.05.011_bib26","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jclinpath-2011-200265","article-title":"HER2 genetic heterogeneity in breast carcinoma","volume":"64","author":"Ohlschlegel","year":"2011","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2022.05.011_bib27","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.humpath.2022.05.011_bib28","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMc0801440","article-title":"HER2 status and benefit from adjuvant trastuzumab in breast cancer","volume":"358","author":"Paik","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2022.05.011_bib29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00428-017-2151-x","article-title":"Prognostic impact of HER-2 subclonal amplification in breast cancer","volume":"471","author":"Di Oto","year":"2017","journal-title":"Virchows Arch"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681772200137X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004681772200137X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:40:37Z","timestamp":1758645637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004681772200137X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":29,"alternative-id":["S004681772200137X"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2022.05.011","relation":{},"ISSN":["0046-8177"],"issn-type":[{"type":"print","value":"0046-8177"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Digital imaging correlation of immunohistochemistry and fluorescence in situ hybridization in breast carcinoma cases with HER2 genetic heterogeneity","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2022.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}